A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

PreDiabetes Clinical Trial

Official title:

A Phase II, Randomized, Placebo - Controlled Crossover Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05803772
• Other study ID #: CAP2022-1
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2023
• Est. completion date: October 23, 2023

Study information

• Verified date: July 2023
• Source: Aphaia Pharma US LLC
• Contact: Abbie Liu, MSc
• Phone: 7872996563
• Email: liu[@]aphaiapharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in participants with pre-diabetes (pathological Oral Glucose Tolerance Test (OGTT)).

Description:

The goal of this Phase II, Randomized, Placebo-Controlled Crossover Proof-of-Concept Study is to evaluate the efficacy of APHD-012 in patients with pre-diabetes (pathological Oral Glucose Tolerance Test (OGTT)). The main questions it aims to answer are: 1. Are there changes in baseline in Area Under the Curve from Time 0 to 2 Hours (AUC0-2) values of Oral Glucose Tolerance Test (OGTT)? 2. Are there changes in biomarkers (e.g. fasting plasma glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR))? Participants will receive study medication or placebo once daily for 6 weeks, followed by washout period of 4 weeks, and subsequent crossover to the other treatment arm for 6 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: October 23, 2023
• Est. primary completion date: October 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male and female subjects 18 - 70 years of age
• Fully vaccinated against SARS-CoV-2.
• Body mass index 25-35 kg/m2
• Subjects with an impaired glucose tolerance defined as: HbA1c values =5.7% and = 6.4%, and/or, Impaired glucose tolerance (glucose between 140 and 199 mg/dL at the 2 hours of the Oral Glucose Tolerance Test (OGTT)) with or without impaired fasting glucose (fasting glucose between 100 and 125 mg/dL)
• Stable body weight: gain or loss in body weight = 5% body weight over last 3 months
• History of at least one unsuccessful effort of lifestyle modification to loose >5% of body weight, completed at least 3 months prior to screening. Subject may have been treated with either diet or exercise alone.
• Willingness to undergo screening and all study procedures and examinations (i.e., physical examinations and laboratory investigations before and after the treatment periods) and to wear a flash glucose monitoring device.
• Ability to comprehend subject information and willingness to sign the informed consent.

Exclusion Criteria:

• Evidence of type 2 diabetes defined by fasting plasma glucose = 126 mg/dL; 2-hour OGTT glucose = 200 mg/dL
• Type I diabetes mellitus
• HbA1c = 6.5%
• History of proliferative retinopathy or maculopathy
• Active COVID-19 infection proven by antigen positive Covid Test
• Treatment with any medication for weight loss within the past 3 months before screening.
• Prior or planned weight loss surgery for obesity
• Recent (within past 12 months) or planned endoscopic treatment for obesity.
• Proven history of bulimia or anorexia nervosa
• Eating habits consisting of eating relevant amounts of food throughout the night (after 10 p.m.; except if working on night shifts)
• Treatment with injectable anti-diabetic medications in the last 3 months (e.g., GLP-1 receptor agonists, insulin)
• Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months
• Confirmed medical history of liver cirrhosis
• Positive test on Viral hepatitis (HbsAG, HCV)
• Positive test on Human immunodeficiency virus (HIV)
• Cholestatic disease
• Alcohol-related liver disease including alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis evidenced by confirmed history of alcohol use, abnormal liver function tests defined below, and complete blood count (CBC), and/or liver biopsy.
• Abnormal liver function tests:
• Transaminases: Alanine aminotransferase (ALT) = 3x upper limit of normal (ULN); or Aspartate aminotransferase (AST) = 3x ULN;
• or Alkaline phosphatase (ALK) =2.5 x ULN
• or Total bilirubin =2 x ULN
• Stage 4 hypertension (systolic blood pressure (SBP) = 180, diastolic BP (DBP) = 110)
• History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator considers a disqualification for participation in the study.
• Prior or current treatment with drugs aimed to treat abnormal glucose homeostasis including oral antidiabetics, incretin analogues and/or insulin.
• History of uncontrolled illness (e.g. depression, psychosis) or behaviour that at the discretion of the investigator might confound the study results or pose additional risk in administering the study procedures.
• Illicit drug abuse
• Alcohol abuse
• Participation in another investigational drug/biologic or medical device study within 30 days of screening or will be enrolled in another investigational drug or medical device study or any study in which active subject participation is required outside normal hospital data collection during the course of the study.
• Failure to provide informed consent.
• Unwillingness or inability to comply with the study protocol or study-related procedures.

Related Conditions & MeSH terms

• Glucose Intolerance
• Glucose Tolerance Impaired
• PreDiabetes
• Prediabetic State

Intervention

Drug:
• APHD-012
Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
• APH-012P
Distal jejunal-release placebo beads

Locations

Country	Name	City	State
Slovakia	ALIAN, s.r.o.	Bardejov
Slovakia	MEDISPEKTRUM s.r.o.	Bratislava

Sponsors (1)

Lead Sponsor	Collaborator
Aphaia Pharma US LLC

Country where clinical trial is conducted

Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in systolic blood pressure (SBP)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Diastolic blood pressure (DBP)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Heart rate (HR)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Triglycerides		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Cholesterol (Total, LDL, HDL)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Fasting plasma insulin		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in HbA1c		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Alanine transaminase (ALT)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Aspartate transaminase (AST)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in Gamma Glutamyl Transferase (GGT)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline Daily average glucose as measured by Flash Glucose Monitoring (FGM)		Day 1 to Day 42; Day 71 to Day 112
Other	Change from baseline in AUC0-2h of OGTT as measured by Flash Glucose Monitoring (FGM)		Day 1 to Day 42; Day 71 to Day 112
Primary	Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samples	The primary efficacy endpoint is the change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) measured in blood samples at the end of each study period (Day 42 and Day 112, respectively). Two baselines will be defined for each period separately (Day 1 and Day 71, respectively).	Day 1 to Day 42; Day 71 to Day 112
Secondary	Change from baseline in fasting plasma glucose concentrations	Change from baseline in fasting plasma glucose concentrations will be measured as ratio to baseline of fasting plasma glucose concentration at week 6 of each study period.	Day 1 to Day 42; Day 71 to Day 112
Secondary	Change from baseline in HOMA IR	Change from baseline in HOMA IR will be measured as ratio to baseline of HOMA-IR at week 6 of each study period	Day 1 to Day 42; Day 71 to Day 112
Secondary	Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE)	A treatment-emergent adverse event is defined as any event not present prior to the initiation of the drug treatment or any event already present that worsens in either intensity or frequency following exposure to the drug treatment	Day 1 to Day 42; Day 71 to Day 112